SCHEMBL16397130

SCHEMBL16397130

COC(=O)Cc1ccccc1OCc1cccc(-c2cc(Cl)cc(C(CO)NC(=O)OC(C)(C)C)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 12/20 0.48
▸ F11 P03951 10/20 0.48
▸ TPSB2 P20231 9/20 0.48
▸ KLKB1 P03952 2/20 0.42
▸ PLG P00747 1/20 0.42
▸ PLAU P00749 1/20 0.42
▸ F7 P08709 1/20 0.42
▸ CTSB P07858 1/20 0.39
▸ CTSS P25774 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ CYP2C9 P11712 1/20 0.37
▸ PTGER1 P34995 1/20 0.37
▸ CTSL P07711 1/20 0.36
▸ CACNA1B Q00975 2/20 0.36
▸ PDCD1 Q15116 1/20 0.36
▸ CD274 Q9NZQ7 1/20 0.36
▸ ITGA4 P13612 1/20 0.35
▸ ITGB7 P26010 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397132 1.00 CFD (0.48) CFDF11TPSB2KLKB1PLG
SCHEMBL17764480 0.93 CFD (0.57) CFDF11TPSB2KLKB1PLG
SCHEMBL17764537 0.93 CFD (0.54) CFDF11TPSB2KLKB1PLG
SCHEMBL16410388 0.93 CFD (0.54) CFDF11TPSB2KLKB1PLG
SCHEMBL16410351 0.90 CFD (0.49) CFDF11TPSB2KLKB1PLG
SCHEMBL17764308 0.90 CFD (0.49) CFDF11TPSB2KLKB1PLG
SCHEMBL16403599 0.87 CFD (0.57) CFDF11TPSB2KLKB1PLG
SCHEMBL17764538 0.86 CFD (0.51) CFDF11TPSB2KLKB1PLG
SCHEMBL16396277 0.86 CFD (0.51) CFDF11TPSB2KLKB1PLG
SCHEMBL16410593 0.85 CFD (0.51) CFDF11TPSB2KLKB1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885F11 17/4885TPSB2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback